A promising therapeutic strategy for RPGR-related RP is a gene replacement therapy where adeno-associated virus (AAV) are injected subretinally to replace the isoform RPGRORF15 of the defective RPGR gene. The gene discussed is RPGR; the disease is retinitis pigmentosa 1.